source
- Novartis pulls Pluvicto prostate cancer label expansion filing in the EUNovartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain fav…Endpoints · 3mo ago↗ source
- Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelicsLilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.BioPharma Dive · 3mo ago↗ source
- Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapyThe new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies suggest most of those who start taking GLP-1 drug…